Stelios Papadopoulos - Apr 13, 2023 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Role
Director
Signature
Christopher Aker, Attorney in Fact
Stock symbol
RGLS
Transactions as of
Apr 13, 2023
Transactions value $
$200,000
Form type
4
Date filed
4/14/2023, 04:39 PM
Previous filing
Jun 17, 2022
Next filing
Jun 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGLS Common Stock Award $200K +222K +43.9% $0.90 728K Apr 13, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated April 13, 2023. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors and an independent committee thereof
F2 Adjusted to reflect 10-to-1 reverse stock split effected June 28, 2022.